glp-1 receptor agonist manufacturers Market Size & Trends 2035 GLP-1 Receptor Agonist Market Size
Description
A report from Jefferies highlighted that while a healthier population is likely to reduce insurance premiums, this would only be seen in new business
Although the use of GLP-1 RAs prior to EGD or colonoscopy has resulted in poor outcomes in terms of poor visibility/preparation scores and the need for aborted/repeated procedures, their use prior to concurrent EGD and colonoscopy might not have the same detrimental effect
Buteau J, Foisy S, Joly E, et al
LaBarre, J
doi: 10.1016/j.bbrc.2009.10.054 41 Portela-GomesGMHoogA
